Condition: Sarcopenia · Oncology · Physical Inactivity · Sponsor: Centre Hospitalier Metropole Savoie
The goal of this clinical trial is to learn about the effect of sarcopenic status on the occurrence of treatment-related toxicity during the first course of anti-cancer treatment in several types of cancers. The main question it aims to answer is : Is sarcopenia a predictive marker for the occurrence of toxicity in the initial phase of cancer treatment? The evaluation will focus on the body composition of the participants, assessed by impedancemetry, and on their muscular performance by standardized physical tests.
This description comes directly from the study's public registry record.
Aurelie FILLON · 04.79.96.58.13 · aurelie.fillon@ch-metropole-savoie.fr
Nathalie MARQUES, Dr · 04.79.96.58.13 · nathalie.marques@ch-metropole-savoie.fr
Always discuss trial participation with your own doctor first.
| Centre Hospitalier Metropole Savoie | Chambéry, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06274268